Association Between Fractional Exhaled Nitric Oxide and Asthma Control

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01197690

Acronym

FeNO_AS

Enrollment

Registered

2010-09-09

Start date

2010-02-28

Completion date

2010-12-31

Last updated

2015-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial Asthma

Keywords

Bronchial asthma, level of control of asthma, fractional exhaled nitric oxide (FeNO), asthma control test (ACT)

Brief summary

The purpose of this study is to determine mean or median of fractional exhaled nitric oxide (FeNO) in Thai atopic asthmatic patients that divided into subgroups due to level of asthma control according to the global initiative for asthma guideline.

Detailed description

From many previous studies, fractional exhaled nitric oxide (FeNO) has many benefits such as non-invasive, easily to perform, less time consume, has direct association with severity of inflammation of bronchial trees and sputum eosinophils, has benefit for diagnosis and monitoring the treatment in asthmatic patients. In Thailand, this field of study is less extend, especially in children population. We hypothesized that in uncontrolled or partly controlled group may have high level of fractional exhaled nitric oxide (FeNO) than controlled group. It is therefore desirable to examine the association between fractional exhaled nitric oxide (FeNO) and level of asthma control among atopic asthmatic Thai children and will be the main objective of this research.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

7 Years to 60 Years

Healthy volunteers

Inclusion criteria

* clinical diagnosis of atopic bronchial asthma * follow up in clinic of allergy and clinical immunology, Siriraj hospital

Exclusion criteria

* smoker or past history of smoking * has chronic disease eg. HIV infection, pulmonary hypertension, systemic lupus erythematosus, liver cirrhosis, gastroesophageal reflux, COPD, bronchiectasis * drink ethanol within 48 hours before enrollment * history of upper or lower respiratory tract infection within 6 weeks before enrollment * drink caffeine within day before enrollment * during pregnancy * history of systemic steroid use within 8 weeks before enrollment

Design outcomes

Primary

Measure	Time frame
fractional exhaled nitric oxide level	10 minutes (average time), on the day of enrollment

Secondary

Measure	Time frame
scores of asthma control test: ACT	5 minutes (average time), on the day of enrollment

Countries

Thailand

Outcome results